The FoCUS project was launched in 2016 with the aim of developing precision financing solutions that address the challenges and financial impact created by durable cell and gene therapies entering the US healthcare market. While these innovative therapies can deliver significant health benefits for patients, the performance and actuarial risk associated with these products are concerns for stakeholders. When combined with the high upfront cost of treatment, the combined uncertainty means that payers face a high level of risk associated with therapy coverage.
Share this Post